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Abstract
 
Plasma von Willebrand factor (vWF) is a multimeric protein that mediates adhesion of platelets
to sites of vascular injury. Only the very large vWF multimers are effective in promoting plate-
let adhesion in flowing blood. A protein disulfide bond reductase in plasma reduces the average
multimer size of vWF secreted by endothelial cells. This activity has been isolated from human
endothelial cell conditioned medium and shown to be the trimeric glycoprotein, thrombospon-
din-1 (TSP-1). Incubation of purified TSP-1 with vWF resulted in formation of thiol-depen-
dent complexes of TSP-1 and vWF, generation of new thiols in vWF, and reduction in the av-
erage multimer size of vWF. The ratio of the concentrations of TSP-1 and vWF in plasma
reflected with average multimer size of vWF. The higher the plasma TSP-1/vWF molar ratio,
the smaller the average vWF multimer size. In addition, administration of TSP-1 to mice re-
sulted in reduction in the average multimer size of plasma vWF. Interaction of TSP-1 with
vWF is mediated by TSP-1 type 1 properdin domains and the vWF A3 domain. These results
indicate that TSP-1 regulates the multimeric size and therefore hemostatic activity of vWF.
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Introduction
 
Binding of platelets to von Willebrand factor (vWF)
 
1
 
 in the
subendothelium of a damaged blood vessel is the initial step
in formation of a hemostatic plug (1). vWF is also the car-
rier for procoagulant factor VIII protecting it from inacti-
vation by activated protein C and factor Xa in the circulat-
ing blood. vWF is synthesized by vascular endothelial cells
and megakaryocytes and circulates in blood as a series of
 
multimers containing a variable number of 
 
 
 
500 kD ho-
modimers (2). The largest vWF multimers have a molecu-
lar mass of 
 
 
 
20,000 kD and are comparable in length to
 
the diameter of a medium platelet (2 
 
 
 
M).
vWF dimers are assembled from pairs of 
 
 
 
250 kD
polypeptide subunits in the endoplasmic reticulum via di-
sulfide bridges between cysteine residues located in the
COOH-terminal regions. Intersubunit disulfide bonds in-
volve one or three of the Cys residues at positions 2,008,
2,010, and 2,048 (3). Subsequently, multimers are formed
by interdimeric disulfide linking of NH
 
2
 
-terminal domains
in a parallel orientation (4). Interdimeric disulfide bonds in-
volve Cys
 
379
 
 and one or more of the Cys residues at posi-
tions 459, 462, and 464 (5).
 
Only the large multimeric forms of vWF are hemostati-
cally active (6). This relates to affinity of vWF for its
ligands. Binding of multimeric vWF to collagen occurs
 
with 
 
 
 
100-fold higher affinity than binding of mono-
meric vWF fragments. Similarly, large vWF multimers
bind to activated platelets with up to 10-fold higher affin-
ity than small multimers, or with 
 
 
 
100-fold higher affinity
than monomeric fragments (for a review, see reference 6).
Large multimers of vWF have considerably higher ristoce-
tin cofactor activity per unit antigen than small multimers
(7), and the unusually large vWF multimers secreted by
endothelial cells have been shown to be more effective
than the largest plasma forms in inducing platelet aggrega-
tion under conditions of high fluid shear (8). Some throm-
botic disorders are characterized by altered vWF multimer
size. Thrombotic thrombocytopenic purpura (TTP) is
usually associated with unusually large vWF multimers in
the blood which are thought to precipitate intravascular
platelet clumping (9). Conversely, lower than average
multimer size characterizes the bleeding diathesis of type II
von Willebrand disease.
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Abbreviations used in this paper:
 
 GSH, reduced glutathione; MPB, 3-(
 
N
 
-
maleimidylpropionyl)biocytin; NEM, 
 
N
 
-ethylmaleimide; PVDF, polyvi-
nylidine difluoride; TSP-1, thrombospondin-1; TTP, thrombotic throm-
bocytopenic purpura; vWF, von Willebrand factor. 
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vWF secreted by cultured endothelial cells into the me-
dium in the presence of plasma cryosupernatant is of
smaller average size than the vWF deposited into the sub-
endothelial matrix (10). Frangos et al. (10) proposed that a
substance in plasma cryosupernatant is responsible for re-
ducing the size of the large vWF multimeric forms secreted
into the vascular lumen to the somewhat smaller vWF
multimers ordinarily found in plasma. They found that the
vWF depolymerizing activity was inactivated by thiol
blocking agents and there was no evidence for proteolysis
of the depolymerized vWF. This prompted Phillips et al.
(11) to suggest that the activity was a type of limited disul-
fide bond reductase.
We recently reported that the conditioned medium of
cultured macrovascular and microvascular endothelial cells
contained an activity which reduced the average multimer
size of plasma or purified vWF (12). The reducing activity
was ablated by pretreatment with heat or thiol blocking
agents, but not by a range of specific proteinase inhibitors.
Reduction in vWF multimer size was associated with for-
mation of new thiols in vWF and there was no evidence
for additional proteolytic processing of vWF. These find-
ings suggested that the disulfide bonds that link the vWF
multimers were being reduced by a vWF reductase se-
creted by endothelial cells. This reductase has been isolated
and shown to be the trimeric glycoprotein, thrombospon-
din-1 (TSP-1).
 
Materials and Methods
 
Proteins and Reagents.
 
Leupeptin, phenylmethylsulfonyl fluo-
ride, soybean trypsin inhibitor, and D-Phe-Pro-Arg-chloro-
methyl ketone were from Calbiochem, and 
 
N
 
-ethylmaleimide
(NEM), reduced glutathione (GSH), and EDTA were from
Sigma-Aldrich. 3-(
 
N
 
-maleimidylpropionyl)biocytin (MPB) was
from Molecular Probes. vWF, TSP-1, and scrambled peptides
were synthesized by Auspep. The peptide purity was 
 
 
 
95%. Pu-
rified vWF from human plasma was a gift from Dr. M. Berndt
(Baker Medical Research Institute, Melbourne, Australia) and
was purified according to Booth et al. (13). TSP-1 was purified
from human platelet concentrates as described previously (14)
with some modifications (15). Buffers containing either 0.1 mM
or 2 mM CaCl
 
2
 
 were used throughout the chromatographic puri-
fication of TSP-1. TSP-1 concentration was calculated using an
absorption coefficient for a 1% solution at 280 nm of 10.9. The
murine anti–TSP-1 monoclonal antibody hybridoma cell line,
HB8432 (16), was obtained from American Type Culture Col-
lection. Antibody was produced in ascites and purified using Pro-
tein G-Sepharose (Amersham Pharmacia Biotech). All other re-
agents were of analytical grade.
 
Normal and TTP Plasmas.
 
Blood was collected by atraumatic
venipucture into citrate. Plasma was prepared by centrifugation at
2,000 
 
g
 
 for 20 min at 4
 
 
 
C and stored at 
 
 
 
20
 
 
 
C.
 
TTP1.
 
Plasma was obtained during therapeutic plasmaphere-
sis of a 73-yr-old female with TTP. For 2 wk before admission
she had been treated with “triple therapy” for 
 
Helicobacter pylorii
 
.
On admission she had severe diarrhea, was confused, and was in
cardiac and renal failure (serum creatinine was 621 mol/liter [60–
111]). The hemoglobin was 99 g/liter (120–153), white cell
count 8.4 
 
 
 
 10
 
9
 
 per liter (4–11), and platelet count 23 
 
 
 
 10
 
9
 
 per
 
liter (150–400). She responded to repeated plasmapheresis and di-
alysis and was discharged well.
 
TTP2.
 
A 2-yr-old girl was admitted to hospital with a fever
and evidence of a petechial rash. Her platelet count and hemoglo-
bin was 15 
 
 
 
 10
 
9
 
 per liter and 62 g/liter, respectively. The blood
film was polychromatic with the occasional nucleated red blood
cell and a moderate number of schistocytes. The reticulocyte
count was raised and the direct antiglobulin test was negative. Her
renal function was normal. A diagnosis of a microangiopathic
hemolytic anemia/probable TTP was made and plasma therapy
commenced. After the infusion of 200 ml of plasma her platelet
count rose progressively to normal over 72 h with gradual resolu-
tion of her hemolytic anemia. She has been readmitted with
thrombocytopenia and a microangiopathic hemolytic anemia on
numerous occasions, usually with an accompanying febrile illness.
Periods of remission have ranged from 1–9 mo. Increments in her
platelet count are usually noted within 48 h of the infusion of a
single unit of plasma. She has not received glucocorticoids and her
glucose-6-phosphate dehydrogenase assay was normal.
 
TTP3.
 
A 29-yr-old man was admitted to hospital with a his-
tory of fever, confusion, malaise, abdominal pain, oral mucosal
bleeding, melena, and renal impairment. On admission he was
severely thrombocytopenic and anemic with a platelet count of
2 
 
 
 
 10
 
9
 
 per liter and hemoglobin of 56 g/liter. A presumptive di-
agnosis of acalculous cholecystitis and immune thrombocytopenia
with associated bleeding was made and the patient commenced
on antibiotic therapy and intravenous Ig infusion. The plasma fi-
brinogen level and D-Dimer assay were normal. He failed to re-
spond to treatment and over the next few days his blood film
demonstrated increasing numbers of fragmented erythrocytes. He
was commenced on plasma exchange with cryosupernatant re-
placement. He responded well with a rapid resolution of his
hemolytic anemia and fever with a slower but progressive im-
provement of his thrombocytopenia and renal impairment.
 
Assays for vWF Multimer Size.
 
TTP plasma was incubated
with 20 mM Hepes, 0.14 M NaCl, 1 mM CaCl
 
2
 
, 1 mM MgCl
 
2
 
,
pH 7.4 buffer, conditioned media of HMEC-1 cells, or the
Hepes buffer containing TSP-1 for 1 or 24 h at 37
 
 
 
C. Volumes
and concentrations of reactants are indicated in the figure leg-
ends. Aliquots of the reactions were diluted 10-fold in the Hepes
buffer and assayed for collagen binding affinity and vWF antigen
as described by Favaloro et al. (17). On some occasions, aliquots
of the reactions were resolved on 1% agarose gel electrophoresis
(18), transferred to polyvinylidine difluoride (PVDF) membrane
(Dupont/NEN Life Science Products), blotted with 2 
 
 
 
g/ml of
horseradish peroxidase–conjugated anti-vWF polyclonal antibod-
ies (Dako), and visualized using chemiluminescence (Dupont/
NEN Life Science Products). Murine plasma vWF was assayed in
the same way except that anti–rat vWF polyclonal antibodies
(Cedarlane) were used.
 
Purification of vWF Reductase.
 
Conditioned medium of HMEC-1
cells was prepared using Nunc Cell Factories. HMEC-1 (
 
 
 
80,000
cells/cm
 
2
 
 of cell factory area) were seeded into cell factories in
MCDB-131 medium (GIBCO BRL) containing 10 ng/ml epi-
dermal growth factor (GIBCO BRL), 1 
 
 
 
g/ml hydrocortisone
(Sigma-Aldrich), and 10% fetal calf serum (GIBCO BRL). When
the cells were at 
 
 
 
80% confluence they were washed twice
with phosphate-buffered saline (Sigma-Aldrich) and incubated
with serum-free MCDB-131 medium at 37
 
 
 
C, 5% CO
 
2
 
 for 30 h.
The conditioned medium was collected, centrifuged at 1200 
 
g
 
for 10 min and passed through a 0.2-
 
 
 
m Millipore filter to re-
move detached cells and cellular debris, and stored at 
 
 
 
20
 
 
 
C. 30
liters of conditioned medium was concentrated to 350 ml using 
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a Amicon spiral-wound concentrator with a 10-kD cutoff mem-
brane. The proteinase inhibitors, leupeptin (10 
 
 
 
M), phenyl-
methylsulfonyl fluoride (1 mM), and soybean trypsin inhibitor
(10 
 
 
 
g/ml) were added to the concentrated medium to minimize
proteolytic degradation of the vWF reductase. The concentrated
medium was applied to a 150-ml column of heparin-Sepharose
(2.5 
 
 
 
 30 cm; Amersham Pharmacia Biotech) equilibrated with
20 mM Hepes, 1 mM CaCl
 
2
 
, 1 mM MgCl
 
2
 
, and 0.02% NaN
 
3
 
,
pH 7.4 buffer. The column was washed with 3 bed volumes of
the Hepes buffer at a flow rate of 0.5 ml/min to elute unbound
proteins and developed with a 2.2-liter linear NaCl gradient from
0 to 1 M in the Hepes buffer. vWF reductase activity eluted at
 
 
 
0.3 M NaCl (
 
 
 
700 ml). The fractions containing vWF reduc-
tase activity (
 
 
 
45 ml) were concentrated to 5 ml, dialyzed against
20 mM Hepes, 0.05 M NaCl, 1 mM CaCl
 
2
 
, 1 mM MgCl
 
2
 
,
0.02% NaN
 
3
 
, pH 7.4 buffer, and applied to a 210-ml column of
Sephacryl S-300 HR (1.5 
 
 
 
 120 cm; Amersham Pharmacia Bio-
tech) at a flow rate of 0.5 ml/min. The vWF reductase activity
eluted at 
 
 
 
85 ml.
 
Electrophoresis and Western Blotting.
 
Samples were resolved on
4–15% SDS-PAGE (19). On one occasion, proteins were re-
duced with 20 mM dithiothreitol and the cysteines alkylated with
40 mM iodoacetamide before SDS-PAGE. On another occasion,
samples were resolved on SDS-PAGE, transferred to PVDF
membrane, and blotted with the HB8432 monoclonal antibody
(used at 2 
 
 
 
g/ml). The murine antibody was blotted with rabbit
anti–mouse peroxidase–conjugated antibodies (Dako; used at
1:2,000 dilution) and detected by chemiluminescence (DuPont/
NEN Life Science Products).
 
Assay for Formation of New Thiols in vWF.
 
The biotin-linked
maleimide, MPB, was used to measure reduction of vWF disul-
fide bond(s) by TSP-1. The protocol was essentially as described
by Xie et al. (12). In brief, purified human vWF (2 
 
 
 
g/ml) was
incubated with 20 mM Hepes, 0.14 M NaCl, 1 mM CaCl
 
2
 
, 1
mM MgCl
 
2
 
, pH 7.4 buffer, HMEC-1–conditioned medium, or
the Hepes buffer containing purified human TSP-1 or peptides
for 60 min at 37
 
 
 
C. Free thiol(s) formed in vWF by reduction of
disulfide bond(s) were labeled with MPB (100 
 
 
 
M) for 10 min at
37
 
 
 
C, and the unreacted MPB was quenched with GSH (200
 
 
 
M) for 10 min at 37
 
 
 
C. The MPB-labeled vWF was incubated
in microtiter plate wells coated with anti–human vWF polyclonal
antibodies and the biotin label was detected using StreptABCom-
plex/HRP (Dako).
 
Assay for TSP-1.
 
The HB8432 monoclonal antibody (100 
 
 
 
l
of 5 
 
 
 
g/ml in 15 mM Na
 
2
 
CO
 
3
 
, 35 mM NaHCO
 
3
 
, 0.02% NaN
 
3
 
,
pH 9.6 buffer) was adsorbed to Nunc PolySorp 96-well plates
overnight at 4
 
 
 
C in a humid environment. Wells were washed
once with 20 mM Hepes, 0.14 M NaCl, pH 7.4 buffer (HBS)
containing 0.05% Tween 20 (HBS/Tween), nonspecific binding
sites blocked by adding 200 
 
 
 
l of 2% BSA in HBS and incubating
for 90 min at 37
 
 
 
C, and then washed two times with HBS/
Tween. Normal plasma was depleted of TSP-1 by immunoaffin-
ity chromatography on HB8432-Sepharose CL-4B matrix and
then spiked with known amounts of purified platelet TSP-1. The
spiked plasmas and normal or patient plasmas were diluted in
HBS/Tween and 100 
 
 
 
l aliquots added to antibody-coated wells
and incubated for 30 min at room temperature with orbital shak-
ing. Plasmas were assayed in triplicate. Wells were washed three
times with HBS/Tween and 100 
 
 
 
l of 5 
 
 
 
g/ml of biotin-labeled
HB8432 antibody added and incubated for 30 min at room tem-
perature with orbital shaking. Labeled HB8432 antibody was pre-
pared using the Biotin-XX Protein Labeling Kit from Molecular
Probes. Detection of bound TSP-1 with the same monoclonal
 
antibody used to coat the wells was possible because of the ho-
motrimeric structure of TSP-1. Wells were washed three times
with HBS/Tween, and 100 
 
 
 
l of 1:100 dilution of StreptAB-
Complex/HRP (Dako) in HBS/Tween was added and incu-
bated for 30 min at room temperature with orbital shaking. Wells
were washed three times with HBS/Tween and the peroxidase
detected as described previously (17). Control wells contained
TSP-1–depleted plasma. Absorbances were a linear function of
TSP-1 concentration over the range 1–100 ng/ml.
 
Assay of Binding of TSP-1 to vWF.
 
Purified human vWF (100
 
 
 
l of 5 
 
 
 
g/ml in 0.1 M NaHCO
 
3
 
, pH 8.3 buffer) were adsorbed
to Nunc PolySorp 96-well plates overnight at 4
 
 
 
C in a humid en-
vironment. Wells were washed once with HBS, nonspecific
binding sites blocked by adding 200 
 
 
 
l of 2% BSA in HBS and
incubating for 90 min at 37
 
 
 
C, and then washed two times with
HBS. Coated wells were incubated with TSP-1 (0 to 10 
 
 
 
g/ml)
in 20 mM Hepes, 0.14 M NaCl, 1 mM CaCl
 
2
 
, 1 mM MgCl
 
2
 
, pH
7.4 buffer containing 0, 5, or 20 mM NEM for 30 min at room
temperature with orbital shaking. On one occasion, wells not
coated with vWF but blocked with BSA were incubated with 10
 
 
 
g/ml TSP-1. The wells were washed four times with Hepes
buffer containing 1 M NaCl and 100 
 
 
 
l of 10 
 
 
 
g/ml anti-TSP1
monoclonal antibody was added and incubated for 30 min at
room temperature with orbital shaking. The wells were washed
three times with HBS and 100 
 
 
 
l of 1:1,000 dilution of rabbit
anti–mouse peroxidase-conjugated antibodies was added and in-
cubated for 30 min at room temperature with orbital shaking.
Wells were washed three times with HBS and the peroxidase de-
tected as described previously (17).
 
Results
 
Reduction in the Average Multimer Size of vWF by HMEC-1
Cells.
 
Incubation of TTP1 patient plasma with the condi-
tioned medium of the human dermal microvascular endo-
Figure 1. Reduction in the average multimer size of vWF by condi-
tioned medium from HMEC-1 cells. (A) TTP1 patient plasma (10  l)
was incubated with Hepes-buffered saline containing 1 mM CaCl2 and
MgCl2 (TTP, lane 1) or the conditioned media of HMEC-1 cells
( ECcm, lane 2) (90  l) for 1 h at 37 C and aliquots of the reaction (10
 l) were resolved on 1% agarose gel electrophoresis. The vWF was trans-
ferred to PVDF membrane and Western blotted using peroxidase-conju-
gated anti-vWF polyclonal antibodies. The bracket highlights the change
in the proportion of large vWF multimers in the population. (B) Aliquots
of the reactions described in panel A were analyzed for vWF antigen lev-
els and collagen binding affinity. The results are expressed as the ratio of
the collagen binding activity and vWF antigen level. The bars and errors
are the mean and SD of triplicate determinations. 
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thelial cell line, HMEC-1 (20), resulted in decrease in the
average multimer size of vWF (Fig. 1 A). Specifically, the
very large multimers were lost (see bracket in Fig. 1 A).
There was negligible endogenous vWF in the HMEC-
1–conditioned medium (not shown). The loss of the large
vWF multimers upon incubation with HMEC-1–condi-
tioned medium was reflected in decrease in affinity of the
vWF for collagen (Fig. 1 B). Affinity of vWF for collagen is
an accurate and sensitive measure of average vWF multi-
mer size (17, 21). Collagen binding was expressed relative
to the vWF antigen level which takes into account any
variation in the total vWF in the assays.
 
Purification of vWF Reductase.
 
The reducing activity se-
creted by endothelial cells was associated with a protein
with an anionic pI that binds heparin and contains reactive
thiol(s) (12). 30 liters of conditioned medium from
HMEC-1 cells was collected (910 mg), concentrated, and
applied to heparin-Sepharose. The bound proteins were
resolved with a linear NaCl gradient. vWF reductase activ-
ity eluted at 
 
 0.3 M NaCl (Fig. 2 A). The peak of activity
was pooled ( 3 mg), concentrated, and gel filtered on
Sephacryl S-300 HR. The vWF reductase activity resolved
in the leading peak ( 0.1 mg; Fig. 2 B). The enzyme had
a molecular mass of  500 kD on SDS-PAGE which re-
duced to  170 kD after reduction and alkylation of the
protein (Fig. 2 C). This subunit structure was very similar
to that of TSP-1, which is a homotrimer of  170 kD sub-
units that is secreted by endothelial cells (22) and functions
in cell–cell and cell–matrix interactions (23). The HMEC-1
protein was recognized by an anti–TSP-1 monoclonal
antibody in Western blot (Fig. 2 D), and immunoprecipi-
tation of TSP-1 from HMEC-1–conditioned medium ac-
counted for all the vWF reductase activity in the medium
(Fig. 2 E).
Reduction in the Average Multimer Size of vWF by TSP-1 In
Vitro. TSP-1 is a major component of platelet  -granules
which is secreted upon platelet activation and aggregation.
TSP-1 was purified to homogeneity from pooled outdated
human platelet concentrates and tested for vWF reductase
activity. Each subunit of TSP-1 contains a free thiol that
can reside on any 1 of 12 different cysteines in the COOH-
terminal Ca2 -binding repeats and globular domain of
TSP-1 (24). TSP-1 can be isolated in two different disul-
fide-bonded conformational states by varying the Ca2  ion
concentration used in the purification buffers. TSP-1 puri-
fied in buffers containing 0.1 mM Ca2  is a homogeneous
TSP-1 population in that the free thiol is at Cys974 (25),
whereas TSP-1 purified in buffers containing 2 mM Ca2 
is probably a heterogeneous population of molecules in
which the free thiol resides on 1 of any 12 Cys (24).
Figure 2. Purification of vWF reductase.
(A) 30 liters of conditioned medium from
the human dermal microvascular endothelial
cell line, HMEC-1, was collected, concen-
trated, and applied to heparin-Sepharose.
The bound proteins were resolved with a
linear NaCl gradient. vWF reductase activ-
ity eluted at  0.3 M NaCl. (B) The peak of
activity from the heparin-Sepharose column
was pooled, concentrated, and gel filtered
on Sephacryl S-300 HR. The vWF reduc-
tase activity resolved in the leading peak.
(C) A sample (30  l) of the pooled activity
from the Sephacryl S-300 HR column was
resolved on 4–15% SDS-PAGE under non-
reducing (lane 1) or reducing (lane 2) con-
ditions and silver stained. The vWF reduc-
tase had a molecular mass of  500 kD
which reduced to  170 kD after reduction
and alkylation of the protein. The positions
of Mr markers are shown at left. (D) Purified
human platelet TSP-1 (50 ng, lane 1) or a
sample (30  l) of the pooled activity from
the Sephacryl S-300 HR column was re-
solved on 4–15% SDS-PAGE under nonre-
ducing conditions, transferred to PVDF
membrane, and blotted with the anti–TSP-1
monoclonal antibody, HB8432. The posi-
tions of Mr markers are shown at left. (E)
HMEC-1–conditioned medium (1 ml) was
incubated alone or with an anti–TSP-1 or
control anti-vWF monoclonal antibody (10
 g/ml) and Protein G-Sepharose beads (50
 l of packed beads) for 1 h at 4 C on a ro-
tating wheel. The Sepharose beads were
pelleted by centrifugation and the superna-
tant was assayed for vWF reductase activity. TTP1 patient plasma (10  l) was incubated with the HMEC-1–conditioned medium ( ECcm) supernatants
(90  l) for 1 h at 37 C and aliquots of the reaction were analyzed for vWF antigen levels and collagen binding affinity. The results are expressed as the ra-
tio of the collagen binding activity and vWF antigen level. The bars and errors are the mean and SD of triplicate determinations.1345 Xie et al.
Both forms of platelet TSP-1 reduced the average multi-
mer size of vWF in buffer (not shown) or in plasma (Fig. 3
A, data for the 0.1 mM Ca2  form of TSP-1 is shown). In
particular, the very large multimers were lost (see bracket
in Fig. 3 A). Decrease in vWF multimer size was associated
with decrease in affinity of vWF for collagen (Fig. 3 B).
TSP-1–mediated reduction in vWF multimer size was
concentration and time dependent (Fig. 3 B). It is note-
worthy that the weight ratio of TSP-1 to vWF, and not the
absolute concentration of TSP-1, influenced the extent of
reduction in vWF multimer size (Fig. 3 B). The effect of
TSP-1 on the collagen binding of vWF shown in Fig. 3 B
was matched by the decrease in vWF multimer size mea-
sured by agarose gel electrophoresis (not shown). Three
different preparations of platelet TSP-1 had the same vWF
reducing activity (not shown), and addition of TSP-1 to
TTP2 and TTP3 patient plasmas also reduced the average
multimer size of the plasma vWF (not shown). The vWF
reductase activity in endothelial cell–conditioned medium
is inhibited by EDTA (12). In accordance with this obser-
vation, chelation of Ca2  with EDTA ablated the vWF re-
ductase activity of TSP-1 (not shown).
The first step in reduction of a disulfide bond is nucleo-
philic attack on the substrate disulfide bond by a reductant
thiol which results in formation of a disulfide-linked com-
plex between the substrate and the reductant. Release of
the reductant from the complex requires nucleophilic at-
tack on the disulfide linkage by another thiol, usually of the
reductant. We reasoned that NEM might trap intermediate
covalent complexes of TSP-1 and vWF by blocking the
TSP-1 thiol responsible for separating TSP-1 and vWF.
Maleimides react rapidly and specifically with cysteine thi-
ols at neutral pH. This prediction was tested by measuring
formation of salt-resistant complexes between TSP-1 and
vWF and the effect of the thiol-blocking reagent, NEM,
on complex formation. Microtiter plate wells coated with
vWF were incubated with TSP-1 in the absence or pres-
ence of NEM and then washed with high salt buffer to
minimize noncovalent interactions between TSP-1 and
vWF. Up to eightfold more TSP-1 bound to vWF in the
presence of NEM (Fig. 3 C). Complex formation increased
with increasing NEM concentration. There was no bind-
ing of TSP-1 to wells not coated with vWF.
Reduction of disulfide bonds in vWF was anticipated to
result in a net increase in free thiols in the vWF population
(12). The biotin-linked maleimide, MPB, was used to mea-
sure the formation of new thiols in vWF upon incubation
with TSP-1. vWF was incubated with TSP-1 and free
Figure 3. Reduction in the average multimer size of
vWF by TSP-1 in vitro. (A) TTP1 patient plasma (10  l)
was incubated with Hepes-buffered saline containing 1
mM CaCl2 (TTP, lane 1) or purified platelet TSP-1 (1  g/
ml, lane 2) in the Hepes/CaCl2 buffer (90  l) for 1 h at
37 C and aliquots of the reaction (10  l) were resolved on
1% agarose gel electrophoresis. The vWF was transferred to
PVDF membrane and Western blotted using peroxidase-
conjugated anti-vWF polyclonal antibodies. The bracket
highlights the change in the proportion of large vWF mul-
timers in the population. (B) TTP1 patient plasma (10  l)
was incubated with HMEC-1–conditioned medium
( ECcm) or purified platelet TSP-1 (0.001 to 100  g/ml)
in Hepes-buffered saline containing 1 mM CaCl2 (90  l)
for 1 or 24 h at 37 C and aliquots of the reaction were ana-
lyzed for vWF antigen levels and collagen binding affinity.
The results are expressed as the ratio of the collagen bind-
ing activity and vWF antigen level. The bars and errors are
the mean and SD of triplicate determinations. (C) Interac-
tion of TSP-1 with vWF. Microtiter plate wells coated
with purified human vWF and blocked with BSA were in-
cubated with purified human TSP-1 (0 to 10  g/ml) in
Hepes-buffered saline containing 1 mM CaCl2 and no
(white bars), 5 mM (hatched bars), or 20 mM (black bars)
NEM for 30 min at room temperature. On one occasion,
wells not coated with vWF but blocked with BSA were in-
cubated with 10  g/ml TSP-1. The wells were washed
with the Hepes buffer containing 1 M NaCl to minimize
noncovalent interactions and the bound TSP-1 was meas-
ured using the anti-TSP1 monoclonal antibody, HB8432,
and peroxidase-conjugated secondary antibody. The bars
and errors are the mean and SD of triplicate determinations.
(D) Generation of new thiols in vWF by TSP-1. Purified
human vWF (2  g/ml) was incubated with Hepes-buffered
saline containing 1 mM CaCl2 (Nil), HMEC-1–condi-
tioned medium (CM), or purified human TSP-1 (0.01 to
100  g/ml) in the Hepes/CaCl2 buffer for 60 min at 37 C.
The reactions were labeled with MPB (100  M) and the unreacted MPB was quenched with GSH (200  M). Aliquots of the reactions were incubated in
microtitre plate wells coated with anti-vWF polyclonal antibodies and the adsorbed vWF was incubated with streptavidin peroxidase to measure the incor-
porated MPB. The bars and errors are the mean and SD of triplicate determinations.1346 Control of vWF Multimer Size by TSP-1
thiol(s) formed in vWF were labeled with MPB and the un-
reacted MPB was quenched with GSH. Aliquots of the re-
actions were incubated in microtiter plate wells coated with
anti-vWF polyclonal antibodies and the adsorbed vWF was
incubated with streptavidin peroxidase to measure the incor-
porated MPB. There was negligible existing free thiols in
the purified vWF (12). Incubation of vWF with either
HMEC-1–conditioned medium or purified TSP-1 resulted
in incorporation of MPB into vWF and the incorporation
increased with increasing TSP-1 concentration (Fig. 3 D).
Chelation of Ca2  in the reactions with EDTA ablated TSP-
1–facilitated formation of free thiols in vWF (not shown).
Correlation of vWF Multimer Size with the Concentration of
TSP-1 in Plasma. The results of Fig. 3 indicated that the
extent of reduction in vWF multimer size was a function of
the ratio of the concentrations of TSP1 and vWF. It was an-
ticipated, therefore, that the molar ratio of TSP-1/vWF
would be higher in plasmas from healthy subjects than in
plasmas from patients with TTP. This ratio was measured in
11 healthy subject plasmas and 3 TTP patient plasmas. A
sensitive enzyme-linked immunosorbent assay for plasma
TSP-1 was developed using the anti–TSP-1 monoclonal
antibody, HB8432 (16), that recognizes the central stalk-like
region of TSP-1 (unpublished data). TSP-1 concentrations
as low as 1 ng/ml were measured using the assay.
The average multimer size of the vWF in the healthy
subject plasmas (CBA/vWFAg of 1.01   0.04 [mean  
SD, n   11]) was significantly lower than that in the TTP
patient plasmas (CBA/vWFAg of 1.10   0.01 [mean   SD
of triplicate determinations], 1.37   0.04, and 1.10   0.02
for TTP1, TTP2, and TTP3 plasmas). The average con-
centration of TSP-1 in the normal plasmas was 81   16
ng/ml (mean   2 SD, n   11), which is in good agree-
ment with other estimates. For instance, Hao et al. (26) re-
ported a mean plasma TSP-1 concentration in 24 healthy
adults of 64   18 ng/ml. The concentration of TSP-1 in
the TTP plasmas was 39   7 ng/ml (mean   2 SD of trip-
licate determinations), 24   1 ng/ml, and 45   1 ng/ml
for TTP1, TTP2, and TTP3, respectively, which is signifi-
cantly lower than the concentration in normal plasma.
Figure 4. Characterization of the binding sites on TSP-1
and vWF. (A) Platelet TSP-1 (10  g/ml) was incubated
with Hepes-buffered saline containing 1 mM CaCl2 and
vWF A3 domain peptide DALGFAVRYLT or scrambled
peptide LGDAVRFATLY (0.01 to 100  M) for 10 min at
37 C. The reaction was started by addition of purified
vWF (2  g/ml) and incubated for 60 min at 37 C. The
vWF was labeled with MPB and detected with streptavidin
peroxidase. The bars and errors are the mean and SD of
triplicate determinations. (B) Purified vWF (2  g/ml) was
incubated with Hepes-buffered saline containing 1 mM
CaCl2 and TSP-1 type 1 peptides CSVTCG, CSTSCG, or
scrambled peptide TVSGCC (0.01 to 100  M) for 10 min
at 37 C. The reaction was started by addition of platelet
TSP-1 (10  g/ml) and incubated for 60 min at 37 C. The
vWF was labeled with MPB and detected with streptavidin
peroxidase. The bars and errors are the mean and SD of
triplicate determinations. (C) Cartoon of the quaternary
structures of vWF and TSP-1 and position of the amino
acid sequences that mediate their interaction. Dimers of
vWF are assembled from subunits via disulfide bridges be-
tween cysteine residues located in the COOH-terminal re-
gions. Multimers are formed from dimers by interdimeric
disulfide linking of NH2-terminal domains in a parallel ori-
entation. The A1 and A3 domains of the vWF subunit are
indicated. We propose that TSP-1 reduces the interdimeric
disulfide bonds (black arrow). The TSP-1 subunit contains
a unique heparin-binding domain at the NH2 terminus,
followed by a connecting region that link three subunits via
interchain disulfide bonds, a procollagen-like module,
three properdin-like or type 1 modules, three epidermal
growth factor–like or type 2 modules, 12 unique calcium-
binding loops (or seven type 3 repeats), and a unique
COOH-terminal globular domain.1347 Xie et al.
The TSP-1/vWFAg ratio in the normal plasmas was
286   54 ng/ml/OD (mean   SD, n   11). The TSP-1/
vWFAg ratio in the TTP plasmas was 169   33 ng/ml/
OD (mean   SD of triplicate determinations), 74   5 ng/
ml/OD and 123   4 ng/ml/OD for TTP1, TTP2, and
TTP3, respectively, which is significantly lower than the
ratio in normal plasma. In addition, there was an inverse re-
lationship between the average vWF multimer size (CBA/
vWFAg) and the TSP-1/vWFAg ratio in the normal and
TTP patient plasmas.
Characterization of the Binding Sites on TSP-1 and vWF.
CD36 is a membrane receptor for TSP-1 on endothelial
cells, platelets, monocytes, and several tumor cell lines.
TSP-1 binds to amino acid residues 87 to 99 within a single
disulfide loop of CD36 (27). Examination of the vWF
amino acid sequence revealed a region of the A3 domain
(DALGFAVRYLT, residues 1,008–1,018) with high ho-
mology to the TSP-1 binding sequence of CD36 (GPY-
TYRVRFLA, residues 89–99). 7 of 11 amino acids are the
same or very similar.
The vWF A3 domain peptide (residues 1,008–1,018) or
a scrambled peptide was synthesized and tested for inhibi-
tion of TSP-1 reduction of vWF. Platelet TSP-1 was pre-
incubated with the peptide and the reaction was started by
addition of vWF. The vWF was labeled with MPB and de-
tected with streptavidin peroxidase as described in Fig. 3 D.
The A3 domain peptide was a potent inhibitor of reduction
of vWF by TSP-1 with half-maximal effect at  0.01  M
(Fig. 4 A). The scrambled peptide had no effect on vWF
reduction up to 10  M.
TSP-1 binds to CD36 via the TSP-1 type 1 properdin
domains. The CSTSCG sequence in the first TSP-1 type 1
repeat and the CSVTCG sequence in the second and third
type 1 repeats are responsible for the interaction with
CD36 (28, 29). The TSP-1 type 1 domain peptides or a
scrambled peptide was synthesized and tested for inhibition
of TSP-1 reduction of vWF. vWF was preincubated with
the peptide and the reaction was started by addition of
TSP-1. The vWF was labeled with MPB and detected with
streptavidin peroxidase as described in Fig. 3 D. The type 1
domain peptides inhibited reduction of vWF by TSP-1
with half-maximal effect at   0.1  M (Fig. 4 B). The
scrambled peptide had no effect at 0.1  M and caused
 50% inhibition at 10  M.
Reduction in the Average Multimer Size of vWF by TSP-1 In
Vivo. The ability of TSP-1 to reduce the average multi-
mer size of vWF in vivo was examined by administering
TSP-1 to mice via intraperitoneal injection and measuring
the consequence for the average multimer size of plasma
vWF. Balb c mice (7 to 9 wk of age) were administered ei-
ther buffer vehicle (n   4) or 1 mg/kg purified human
platelet TSP-1 (n   4) via 0.1 ml intraperitoneal injections.
There were two male and two female mice in each group.
Blood was collected by cardiac puncture into EDTA 24 h
later and the plasma was analyzed in triplicate for vWF an-
tigen levels and collagen binding affinity. The average mul-
timer size of the plasma vWF was significantly lower (P  
0.05) in mice treated with TSP-1 (CBA/vWFAg   0.83  
0.05) than with buffer vehicle (CBA/vWFAg   1.65  
0.32). The concentration of human TSP-1 in the plasma of
the treated mice 24 h after injection was measured using
the TSP-1 assay and found to be  1  g/ml.
Discussion
TSP-1 reduced the average multimer size of vWF in
vitro and in vivo. Reduction in vWF multimer size was as-
sociated with formation of thiol-dependent complexes of
TSP-1 and vWF and generation of new thiols in vWF.
The extent of reduction of vWF by TSP-1 was depen-
dent on the molar ratio of TSP-1 and vWF and time of in-
cubation and not simply on the absolute concentration of
TSP-1. In experiments with purified TSP-1 and  1  g/ml
plasma vWF, for example, the optimal TSP-1 concentra-
tion for reduction in 1 h was  0.1  g/ml compared with
 0.01  g/ml in 24 h. The weight concentrations of vWF
and TSP-1 in normal plasma are  10  g/ml (30) and  0.1
 g/ml (our results and reference 26), respectively. Assum-
ing a weight-average Mr for vWF of  2   106 (31) and Mr
for TSP-1 of 0.5   106, the molar concentrations of vWF
and TSP-1 in normal plasma are  5 nM and  0.2 nM, re-
spectively. TSP-1 targets the very large vWF multimers in
Figure 5. Model for reduction of vWF by TSP-1. TSP-1 contains
three unpaired cysteines per molecule, presumably one per subunit (refer-
ences 24 and 25). These thiols are only partially accessible to alkylation by
NEM and inaccessible to alkylation by iodoacetamide in the Ca2 -replete
form of TSP-1 (reference 24). We suggest that interaction of vWF with
TSP-1 results in a conformational change in TSP-1 which triggers the re-
duction of vWF intersubunit disulfide bonds. Chelation of Ca2  with
EDTA inhibits reductase activity. Nucleophilic attack by a TSP-1 thiol
on a vWF intersubunit disulfide bond results in reduction of the disulfide
bond with formation of an intermediate disulfide-linked complex be-
tween TSP-1 and vWF. Nucleophilic attack by a second TSP-1 thiol re-
sults in release of vWF and formation of an intramolecular disulfide bond
in TSP-1. Reduction of one disulfide bond in vWF is represented but
two, three, or four intersubunit disulfide bonds may need to be reduced
to change multimeric size (reference 5). Each step in the model is poten-
tially reversible. The model predicts the formation of intermediate cova-
lent complexes between TSP-1 and vWF, which may be trapped with
thiol-blocking agents such as NEM (see Fig. 3 B), and a net increase in
free cysteine thiols in the vWF population (see Fig. 3 C).1348 Control of vWF Multimer Size by TSP-1
plasma, which represent  10% of the total vWF popula-
tion (see Fig. 3 A). The moles of TSP-1 and moles of vWF
it reacts with in normal plasma, therefore, is roughly equal.
Our findings predicted that the higher the plasma TSP-
1/vWF molar ratio the smaller the average vWF multimer
size. We anticipated, therefore, that the molar ratio of
TSP-1/vWF would be lower in plasmas from patients with
TTP than in plasmas from healthy subjects. This was the
case in the plasmas of the three patients with TTP exam-
ined in this study. The concentration of TSP-1 in the TTP
patient plasmas was  55% of the average concentration in
plasmas from healthy subjects. Similarly, the TSP-1/vWF
ratio in the patient plasmas was  59% of the average ratio
in normal plasma. Moreover, there was an inverse relation-
ship between the average vWF multimer size and the TSP-
1/vWFAg ratio of the plasmas.
These observations define a disulfide bond reductase/
isomerase activity of TSP-1. Reductase/isomerase active
sites are characterized by closely spaced cysteines in the
consensus sequence, CGXC (32). The cysteine thiols cycle
between the reduced dithiol and oxidized disulfide bond in
coordination with a dithiol or disulfide of a protein sub-
strate which can result in reduction, formation, or inter-
change of disulfide bonds in the protein substrate. There is
a CGAC sequence in the first type 2 repeat of TSP-1 but
there is no evidence that these two cysteines are redox ac-
tive (24). In contrast, a complex intramolecular disulfide
interchange operates in the COOH-terminal Ca2 -binding
repeats and globular domain of TSP-1 (24). These disulfide
exchange events are likely to be involved in reduction of
vWF by TSP-1 because of the requirement for Ca2  ions
for TSP-1 reductase activity. Different disulfide-bonded
forms of TSP-1 have different Arg-Gly-Asp (RGD)-depen-
dent cell adhesive activity (25), inhibit neutrophil enzymes
with markedly differing potencies (33, 34), bind Ca2  with
different stoichiometries (35), and bind platelet-derived
growth factor with very different affinities (15).
Interaction of TSP-1 with vWF is mediated by TSP-1
type 1 properdin domains and the vWF A3 domain. We
propose that binding of the TSP-1 type 1 domain(s) to the
vWF A3 domain(s) enables engagement of the TSP-1 C-ter-
mini with the vWF interdimer disulfide bonds. A model
for the mechanism by which TSP-1 reduces vWF multi-
mer size is shown in Fig. 5. TSP-1 preferentially reduced
the large vWF multimers. We suggest that the multimeric
size of vWF will be balanced by the avidity of TSP-1 for
vWF, which will decrease as vWF multimer size decreases,
and the potential for reformation of intersubunit disulfide
bonds between vWF molecules, which will increase as the
number of smaller vWF molecules increase (12). Frangos et
al. (10) showed that small vWF multimers can react to form
larger multimers in plasma.
The average multimer size of vWF can be reduced by
cleavage of the Tyr842-Met843 peptide bond by a plasma
metalloproteinase. Deficiency of this enzyme is associated
with abnormally large vWF multimers in the blood of pa-
tients with chronic relapsing TTP (36, 37). The relation-
ship between TSP-1 and the plasma metalloproteinase for
control of vWF multimer size is unknown but they are
clearly separate activities (12). It is possible that TSP-1 and
the vWF cleaving metalloproteinase act in concert to con-
trol of the average multimer size of plasma vWF (9). It is
noteworthy that vWF binds to the type 1 domains of TSP-1,
which are the same domains that bind CD36. Anti-CD36
antibodies have been identified in patients with TTP (38).
It may be that perturbation of the TSP-1–CD36 interac-
tion in TTP contributes to the abnormally large vWF mul-
timers associated with this disease.
The prevalence of large vWF multimers in the plasma
vWF population determines vWF’s hemostatic activity (6).
Our findings imply that TSP-1 is involved in normal con-
trol of vWF hemostatic activity, and perturbation of secre-
tion or function of TSP-1 or polymorphism in the TSP-1
gene may contribute to thrombotic and vascular disorders.
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